ACELRYIN, Inc is a late stage clinical biopharma company based in Agoura Hills, CA, focused on accelerating the development and delivery of transformative medicines for patients. Led by a team of veteran biopharma executives, they are actively investigating the potential of izokibeplonigutamab in diseases where differentiated inhibition of validated targets may help address unmet patient needs.
With a corporate culture of courageous caring and a commitment to placing patients first, ACELYRIN is dedicated to investing in, developing, and commercializing clinically meaningful therapies. Their pipeline includes promising treatments such as lonigutamab, with recent positive proof of concept data demonstrating rapid improvements for patients.
Generated from the website